HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knopf, W. D. Search for Related Content PubMed Articles by Knopf, W. D.

i2 Innovation in Intervention Summit

Cardiac Services of St. Joseph’s Hospital of Atlanta, Atlanta Cardiology Group of Georgia, Atlanta, Georgia.

View larger version (18K): [in a new window]   Figure 1 Nine-month clinical outcome for insulin-treated diabetic patients enrolled in the Strategic Transcatheter Evaluation of New Therapies (STENT) trial. Completed nine-month follow-up: 5,566, 93.7%. p = NS for all. Blue bars = sirolimus-eluting stent; yellow bars = paclitaxel-eluting stent. MACE = major adverse cardiac events; MI = myocardial infarction; TVR = target vessel revascularization.

View larger version (28K): [in a new window]   Figure 2 Clinical Performance and Angiographic Results in Absorbable Metal Stents (PROGRESS-AMS) study: volumetric intravascular ultrasound parameters. No late incomplete opposition; no adverse edge effect. *p < 0.01. Blue bars = post-implantation; yellow bars = four-month follow-up. EEM = external elastic membrane.

View larger version (35K): [in a new window]   Figure 3 Reduction in headache burden (frequency x duration) in the Migraine Intervention with StarFlex Technology (MIST) trial. p = 0.033. Blue bars = baseline; yellow bars = analysis.